Related Experiment Video

Updated: Mar 7, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.0K

[How I treat acute myeloid leukemia with t (8;21)]

H H Zhu, X J Huang

    Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
    |February 22, 2017
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    878
    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 18, 2013

    18.7K

    Related Experiment Videos

    Last Updated: Mar 7, 2026

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    1.0K
    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    878
    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
    10:49

    Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

    Published on: September 18, 2013

    18.7K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.8K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.8K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    6.3K
    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.3K

    Articles linked to this work by shared authors, journal, and citation graph.

    [Prognostic analysis of NUP98 rearrangement in patients with pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Advances in the prevention and treatment of acute graft-versus-host disease with cellular and novel targeted immunotherapy].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Secondary treatment-free remission in chronic myeloid leukemia in the chronic phase: a case series and literature review].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Haploidentical hematopoietic stem cell transplantation for advanced myelodysplastic syndrome patients with recurrent genetic abnormalities].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [High-throughput sequencing in identifying somatic hypermutation in immunoglobulin heavy chain variable regions with complex clonal backgrounds].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2025

    [Application and challenges of the clinical decision support system in hematological diseases].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Prognostic significance of IKZF1 alterations in acute B-lymphoblastic leukemia and the choice of transplantation strategy].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Somatic and immune profiling of chemotherapy-associated aplastic anemia: a comparison with primary aplastic anemia and cancer without aplastic anemia].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    [Construction of a methionine metabolism-related prognostic signature and the effect of targeting methionine metabolism on diffuse large B-cell lymphoma].

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026

    Emerging biodegradable nanomaterials for innovative tumor immunotherapy.

    Journal of materials chemistry. B·2026

    Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

    Haematologica·2026

    The First Pan-African Survey of Interventional Pulmonology: Current Practice, Training Gaps, and Barriers.

    Journal of bronchology & interventional pulmonology·2026

    Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.

    Journal of inflammation research·2026

    Tissue and blood-based predictive biomarkers in hepatocellular carcinoma immunotherapy: synthesis of 2023-2026 evidence and a proposed clinical integration framework.

    Frontiers in oncology·2026

    Adjuvant treatment of gastrointestinal stromal tumors (GIST)-state of the art, controversies, and future directions.

    ESMO gastrointestinal oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us